| Literature DB >> 28240304 |
Hugo You-Hsien Lin1,2,3,4,5,6, Yu-Li Lee3,7, Kun-Der Lin2,7, Yi-Wen Chiu1, Shyi-Jang Shin7, Shang-Jyh Hwang1,3,4, Hung-Chun Chen1, Chi-Chih Hung1.
Abstract
Glomerulosclerosis and tubulointerstitial fibrosis are associated with lower renal parenchymal elasticity. This study was designed to evaluate the predictive ability of renal elasticity in patients with chronic kidney disease (CKD). 148 non-CKD patients and 227 patients with CKD were recruited. 145 (38.7%) were female, 166 (73.1%) had diabetes, the mean estimated glomerular filtration rate (eGFR) was 33.9 ± 15.8 ml/min/1.73 m2 and the median urinary protein-to-creatinine ratio (UPCR) 502 (122-1491) mg/g. Patients with later stages of CKD had lower renal elasticity values, indicating stiffer kidneys (p < 0.001), and smaller kidney (p < 0.001). Renal elasticity correlated with log-transformed UPCR (β = -7.544, P < 0.001). Renal length correlated with age (β = -0.231, P < 0.001), sex (β = -3.730, P < 0.001), serum albumin level (β = -3.024, P = 0.001), body mass index (β = 0.390, P = 0.009) and eGFR (β = 0.146, P < 0.001). In fully-adjusted logistic regression model, the odds ratio (OR) per 10 unit change in renal elasticity for rapid renal deterioration was 0.928 (95% CI, 0.864-0.997; P = 0.042). The OR per 1 mm change in renal length for rapid renal deterioration was 1.022 (95% CI, 0.994-1.050; P = 0.125). Renal elasticity is associated with proteinuria and rapid renal deterioration in patients with CKD.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28240304 PMCID: PMC5327389 DOI: 10.1038/srep43303
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Patient characteristics by CKD stage.
| Variable | All | Non-CKD | CKD stage 3a | CKD stage 3b | CKD stage 4 | CKD stage 5 | |
|---|---|---|---|---|---|---|---|
| No. of patients | 375 | 148 | 66 | 81 | 44 | 36 | — |
| Age (yr) | 63.2 ± 15.4 | 53.3 ± 15.0 | 70.2 ± 10.0 | 70.6 ± 12.4 | 71.2 ± 12.4 | 64.8 ± 12.5 | 0.312 |
| Gender (female) | 145 (38.7%) | 61 (41.2%) | 22 (33.3%) | 22 (27.2%) | 22 (50.0%) | 18 (50.0%) | 0.940 |
| Height (cm) | 162.5 ± 8.6 | 164.0 ± 8.6 | 162.0 ± 7.4 | 162.8 ± 7.5 | 158.8 ± 10.3 | 160.6 ± 9.0 | 0.042 |
| Body weight (Kg) | 64.8 ± 11.7 | 63.4 ± 11.2 | 65.9 ± 11.5 | 66.9 ± 11.0 | 65.3 ± 10.9 | 62.5 ± 16.1 | 0.263 |
| BMI (Kg/m2) | 24.4 ± 3.4 | 23.5 ± 3.5 | 25.0 ± 3.4 | 25.2 ± 3.5 | 25.8 ± 3.4 | 23.9 ± 4.1 | 0.159 |
| Diabetes Mellitus | 223 (59.5%) | 57 (38.5%) | 47 (71.2%) | 60 (74.1%) | 35 (79.5%) | 24 (66.7%) | 0.105 |
| Hypertension | 103 (27.5%) | 18 (12.2%) | 19 (28.8%) | 29 (35.8%) | 19 (43.2%) | 18 (50.0%) | <0.001 |
| eGFR (ml/min/1.73 m2) | 58.8 ± 36.7 | 97.0 ± 24.7 | 50.7 ± 5.9 | 38.3 ± 3.9 | 21.9 ± 4.2 | 7.7 ± 3.7 | <0.001 |
| UPCR (mg/gm) | 137 (40–687) | 30 (30–66) | 91 (44–209) | 403 (101–1123) | 948 (526–3951) | 2063 (1186–4437) | < 0.001 |
| Renal elasticity | 64.5 ± 39.5 | 75.1 ± 37.8 | 72.9 ± 37.6 | 59.3 ± 40.3 | 48.3 ± 33.8 | 36.6 ± 33.0 | <0.001 |
| Liver elasticity | 80.9 ± 24.1 | 75.2 ± 26.1 | 85.9 ± 19.8 | 79.9 ± 23.2 | 85.6 ± 20.9 | 87.4 ± 22.2 | 0.036 |
| Kidney to liver elasticity ratio | 0.9 ± 0.7 | 1.1 ± 0.7 | 0.9 ± 0.5 | 0.8 ± 0.7 | 0.6 ± 0.4 | 0.4 ± 0.4 | <0.001 |
| Renal length (mm) | 97.9 ± 11.6 | 104.2 ± 9.0 | 95.9 ± 9.7 | 94.8 ± 10.3 | 93.3 ± 13.0 | 88.2 ± 12.5 | <0.001 |
| Renal width (mm) | 45.6 ± 6.4 | 45.4 ± 6.5 | 46.2 ± 6.0 | 46.3 ± 5.7 | 45.2 ± 7.0 | 43.9 ± 7.5 | 0.779 |
| Renal cortex thickness (mm) | 9.0 ± 3.7 | 9.7 ± 5.0 | 8.8 ± 2.4 | 8.6 ± 2.2 | 8.5 ± 2.0 | 8.4 ± 3.1 | 0.003 |
| Hemoglobin (g/dl) | 12.6 ± 2.4 | 13.9 ± 1.8 | 12.8 ± 2.1 | 12.4 ± 2.0 | 11.3 ± 2.0 | 8.9 ± 1.1 | <0.001 |
| Sugar (AC) (mg/dl) | 158.9 ± 93.4 | 147.5 ± 85.1 | 144.4 ± 65.8 | 175.3 ± 115.9 | 178.0 ± 113.0 | 171.6 ± 78.0 | 0.018 |
| HbA1c (%) | 7.1 ± 2.0 | 7.2 ± 2.2 | 6.9 ± 1.6 | 7.4 ± 2.0 | 7.1 ± 2.3 | 6.6 ± 1.3 | 0.424 |
| Total cholesterol (mg/dl) | 188 (158–219) | 197 (155–219) | 180 (145–214) | 194 (153–232) | 160 (117–234) | 207 (148–226) | 0.237 |
| Triglyceride (mg/dl) | 127 (78–179) | 106 (63–182) | 95 (59–147) | 137 (82–191) | 132 (61–194) | 151 (113–205) | 0.012 |
| Uric acid (mg/dl) | 6.8 ± 2.3 | 5.8 ± 2.2 | 7.0 ± 2.5 | 7.2 ± 1.9 | 7.9 ± 1.8 | 8.2 ± 2.0 | <0.001 |
| Albumin (g/dl) | 4.1 ± 0.6 | 4.3 ± 0.6 | 4.0 ± 0.6 | 4.0 ± 0.6 | 3.9 ± 0.6 | 3.8 ± 0.6 | <0.001 |
| K (mEq/l) | 3.9 ± 0.7 | 3.7 ± 0.6 | 3.9 ± 0.6 | 4.1 ± 0.6 | 4.3 ± 0.7 | 4.4 ± 0.7 | <0.001 |
| HCO3 (mEq/l) | 23.5 ± 5.3 | 24.8 ± 5.4 | 23.4 ± 4.6 | 23.7 ± 5.5 | 21.4 ± 4.8 | 20.2 ± 4.2 | <0.001 |
| Follow-up days | 517 (180–1126) | 594 (180–1156) | 425 (178–905) | 640 (204–1080) | 548 (204–981) | 510 (182–974) | 0.315 |
| GFR slope (ml/min/1.73 m2/yr) | −0.5 (−4.6 to 0.4) | 0.0 (−0.9 to 2.7) | 0.0 (−6.9 to 0.9) | −2.6 (−10.4 to 0.0) | −0.5 (−19.3 to 12.3) | −3.5 (−9.2 to 0.2) | <0.001 |
| Rapid renal function progression | 89 (23.7%) | 28 (18.9%) | 10 (15.2%) | 20 (24.7%) | 18 (40.9%) | 13 (36.1%) | 0.006 |
CKD: chronic kidney disease; BMI: body mass index; eGFR: estimated glomerular filtration rate; HbA1C: glycated haemoglobin; K: potassium; HCO3: bicarbonate.
Data are presented as mean ± standard error, median (interquartile range), or count (percentage).
Figure 1Box plots of (a) real time elastography for non-CKD patients and patients with CKD stage 3a to 5; (b) renal length; (c) kidney-to-liver elasticity ratio.
Figure 2Box plots of (a) real time elastography for non-CKD patients and patients with UPCR < 150, 150–500, 500–1000 and >1000 mg/g; (b) renal length; (c) kidney-to-liver elasticity ratio.
Linear regression for renal elasticity, renal length, and kidney-to-liver elasticity ratio.
| Renal elasticity | Renal length | Kidney to Liver Elasticity ratio | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| β | 95% CI | β | 95% CI | Β | 95% CI | |||||
| eGFR (ml/min/1.73 m2) | 0.076 | −0.055 to 0.206 | 0.255 | 0.184 | 0.148 to 0.220 | <0.001 | 0.001 | −0.001 to 0.003 | 0.214 | |
| Log-transformed UPCR | −7.397 | −10.082 to −4.711 | <0.001 | 0.902 | 0.163 to 1.641 | 0.017 | −0.136 | −0.179 to −0.092 | <0.001 | |
| Age (yr) | 0.127 | −0.161 to 0.416 | 0.387 | −0.218 | −0.291 to −0.146 | <0.001 | 0.001 | −0.001 to 0.003 | 0.466 | |
| female vs. male | 3.199 | −4.666 to 11.064 | 0.424 | −4.138 | −6.116 to −2.160 | <0.001 | −0.127 | −0.171 to −0.084 | <0.001 | |
| DM | −0.989 | −9.293 to 7.315 | 0.815 | 2.200 | 0.112 to 4.289 | 0.039 | 0.012 | −0.006 to 0.031 | 0.193 | |
| BMI | 0.120 | −1.040 to 1.280 | 0.839 | 0.426 | 0.134 to 0.718 | 0.004 | −0.001 | −0.005 to 0.004 | 0.777 | |
| eGFR (ml/min/1.73 m2) | 0.104 | −0.045 to 0.253 | 0.171 | 0.151 | 0.114 to 0.189 | <0.001 | 0.091 | −0.034 to 0.217 | 0.154 | |
| Log-transformed UPCR | −7.222 | −9.952 to −4.492 | <0.001 | 0.675 | −0.012 to 1.361 | 0.054 | −0.178 | −0.310 to −0.045 | 0.009 | |
| Age (yr) | 0.130 | −0.161 to 0.421 | 0.382 | −0.231 | −0.304 to −0.159 | <0.001 | −0.001 | −0.005 to 0.004 | 0.774 | |
| female vs. male | 2.234 | −5.990 to 10.458 | 0.594 | −3.730 | −5.770 to −1.690 | <0.001 | 0.065 | −0.066 to 0.196 | 0.329 | |
| DM | −0.924 | −9.335 to 7.486 | 0.829 | 1.711 | −0.376 to 3.797 | 0.108 | −0.179 | −0.313 to −0.045 | 0.009 | |
| BMI | 0.210 | −0.973 to 1.394 | 0.727 | 0.390 | 0.096 to 0.684 | 0.009 | 0.015 | −0.004 to 0.034 | 0.125 | |
| eGFR (ml/min/1.73 m2) | 0.121 | −0.034 to 0.276 | 0.126 | 0.146 | 0.108 to 0.185 | <0.001 | 0.001 | −0.001 to 0.004 | 0.283 | |
| Log-transformed UPCR | −7.544 | −10.469 to −4.619 | <0.001 | 0.560 | −0.166 to 1.286 | 0.130 | −0.138 | −0.184 to −0.091 | <0.001 | |
| Hemoglobin (g/dl) | −0.886 | −3.052 to 1.280 | 0.422 | 0.345 | −0.192 to 0.882 | 0.207 | −0.024 | −0.059 to 0.010 | 0.171 | |
| Albumin (g/dl) | 1.047 | −6.248 to 8.342 | 0.778 | −3.024 | −4.834 to −1.214 | 0.001 | 0.012 | −0.104 to 0.129 | 0.837 | |
UPCR: urine protein to creatinine ratio; DM: diabetes mellitus; BMI: body mass index; eGFR: estimated glomerular filtration rate.
Logistic regression for rapid renal progression by renal elasticity, renal length, and kidney-to-liver elasticity ratio in patients with CKD stages 3-5.
| Renal elasticity (per 10 unit) | Renal length (per 1 mm) | Kidney to Liver Elasticity ratio (per 10%) | ||||
|---|---|---|---|---|---|---|
| OR | OR | OR | ||||
| Unadjusted | 0.901 (0.844–0.962) | 0.002 | 1.014 (0.993–1.035) | 0.202 | 0.928 (0.885–0.923) | 0.002 |
| Model 1 | 0.901 (0.843–0.963) | 0.002 | 1.013 (0.989–1.038) | 0.295 | 0.926 (0.882–0.973) | 0.002 |
| Model 2 | 0.925 (0.862–0.992) | 0.029 | 1.031 (1.004–1.059) | 0.026 | 0.944 (0.897–0.993) | 0.026 |
| Model 3 | 0.928 (0.864–0.997) | 0.042 | 1.022 (0.994–1.050) | 0.125 | 0.942 (0.894–0.992) | 0.030 |
Model 1 adjusts for age, sex, and diabetes.
Model 2 adjusts for covariates in model 1 plus eGFR and log-transformed UPCR.
Model 3 adjusts for covariates in model 2 plus BMI, hemoglobin and albumin.
Figure 3Box plots of (a) real time elastography for non-CKD patients and patients with diabetic CKD stage 3a to 5; (b) renal length.
Figure 4Box plots of (a) real time elastography for non-CKD patients and patients with non-DM CKD stage 3a to 5; (b) renal length.
Figure 5Foresttree plot of the OR per 1 unit increase of elasticity for rapid renal progression.